| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27N7O3S2 |
| Molecular Weight | 513.636 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)N1CCN(CC2=CC3=C(S2)C(=NC(=N3)C4=CC=CC5=C4C=NN5)N6CCOCC6)CC1
InChI
InChIKey=LHNIIDJUOCFXAP-UHFFFAOYSA-N
InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
Pictilisib is an oral potent inhibitor of class I PI3K with nanomolar activities against p110alpha, p110beta, p110delta, and p110gamma. The drug was developed for the treatment of solid tumors and reached phase II in patients with breast cancer and lung carcinoma, however its development was terminated.
CNS Activity
Approval Year
Sourcing
Sample Use Guides
Patients with breast cancer receive paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle) with 260 mg pictilisib (daily on days 1-5 every week).
Route of Administration:
Oral
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
